/assets/production/practices/aa9b9f3c1f99fe2a6c0abeac16823d73901f7687/images/2843508.png)
Traditional TMS requires patients to come to the clinic every weekday for six to eight weeks for up to 36 separate visits. This can be a significant burden for people already struggling with depression. AMPA One-Day TMS solves this by compressing that entire course of treatment into a single structured day: 20 brief three-minute stimulation sessions delivered with rest breaks in between, which may be paired with medications given beforehand to "fertilize the soil" of the brain and make it more receptive to each pulse. Early clinical data from the ONE-D study suggests this approach may be feasible, safe, and well-tolerated, with an 87.5% response rate at six weeks. These results that compare favorably to traditional TMS. You arrive in the morning, complete all 20 sessions throughout the day with breaks and lunch, and drive yourself home by evening with no restrictions and no sedation. AMPA TMS can be a genuinely practical option for people who cannot commit to weeks of daily clinic visits.
AMPA TMS is FDA approved for patients 18 and over who suffer from Major Depressive Disorder, especially those who have not responded to or cannot tolerate antidepressant medications, or those who want a non-medication approach. No specific number of prior medication trials required. AMPA TMS is also approved for patients 15-17 as an off-label treatment.
Published research, such as this article on ScienceDirect in 2025 supports an 87.5% response for single-day AMPA TMS treatment.